Abstract
The current standard of care for patients with classic galactosemia (CG) involves lifelong dietary restriction of high galactose foods, including most dairy products. Here, we present the results of a pilot study testing whether pretreatment with GY007, a strain of baker's yeast selected to metabolize galactose despite the presence of other sugars, would be sufficient to prevent the metabolic impact of dietary galactose exposure in a GALT-null rat model of CG. Specifically, we dosed cohorts of adolescent GALT-null rats with either (a) placebo alone, (b) placebo followed by galactose, or (c) GY007 yeast followed by galactose. All rats were treated 3 times daily for 8 consecutive days, for a combined daily dose of almost 27 mg galactose per rat. Wild-type rats dosed with placebo served as controls. All rats also had ad libitum access to water and chow that contained about 0.15% calories from galactose. Rats grew at the expected pace for the duration of the study regardless of treatment group. To test the metabolic efficacy of the GY007 pretreatment, we followed galactose, galactitol, and gal-1P longitudinally in blood, and at euthanasia in brain and liver. In both liver and red blood cells, most metabolites remained near placebo levels despite the galactose exposure, limiting our ability to test the efficacy of GY007 pretreatment in those tissues. However, in both plasma and brain, metabolites showed a significant elevation following galactose exposure, and this rise was prevented by pretreatment with GY007. These results demonstrate the potential of GY007 yeast to prevent the metabolic consequences of transient low-level dietary galactose exposure in GALT deficiency.